Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Toh

Allergy & Immunology New York, NY Medical Doctor

NPI 1013206085 CMS profile 648485

620 Columbus Ave Ste 2, New York, NY 10024

Open in the dashboard

General payments

$24,966

790 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Toh of New York, NY is reported in the CMS Open Payments database as having received $24,966 across 790 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,893 139
2024 General $2,240 88
2023 General $4,710 117
2022 General $3,810 185
2021 General $3,215 102
2020 General $1,319 63
2019 General $1,779 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Toh
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jennifer Toh were reported at $7,893. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jennifer Toh Allergy & Immunology median Middle half National median
2019 $1,779 $594 $163–$1,512 $163
2020 $1,319 $426 $106–$1,233 $114
2021 $3,215 $638 $157–$1,708 $132
2022 $3,810 $790 $205–$1,961 $149
2023 $4,710 $852 $220–$2,147 $160
2024 $2,240 $865 $203–$2,267 $164
2025 $7,893 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $4,330 82 payments
  2. AstraZeneca Pharmaceuticals LP $3,026 84 payments
  3. ARS Pharmaceuticals Operations, Inc. $2,948 6 payments
  4. Blueprint Medicines Corporation $2,130 14 payments
  5. Genentech USA, Inc. $1,991 36 payments
  6. OptiNose US, Inc. $1,907 32 payments
  7. GlaxoSmithKline, LLC. $1,799 182 payments
  8. Novartis Pharmaceuticals Corporation $723 28 payments
  9. kaleo, Inc. $686 37 payments
  10. Pfizer Inc. $534 35 payments
  11. Other $4,893 254 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,935 781 payments
  2. Consulting Fee $4,706 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
  4. Honoraria $1,588 2 payments
  5. Travel and Lodging $216 1 payment
  6. Education $21 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $3,755 116 payments
  2. NEFFY $2,948 6 payments
  3. Xolair $2,076 35 payments
  4. Xhance $1,907 32 payments
  5. FASENRA Respiratory $1,051 35 payments
  6. TRELEGY ELLIPTA $932 93 payments
  7. SYMBICORT $789 10 payments
  8. FASENRA Respiratory $758 8 payments
  9. BEVESPI AEROSPHERE $698 4 payments
  10. TEZSPIRE $611 24 payments
  11. Other $9,427 526 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

899

Median for Allergy/ Immunology: 449

Drug cost

$366,455

Median for Allergy/ Immunology: $169,700

Branded share of claims

23%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 28 $108,522
Dupixent Syringe Dupilumab Brand 25 $95,606
Xolair Omalizumab Brand 24 $74,389
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $40,928
Epinephrine Generic 73 $17,412
Breo Ellipta Fluticasone/Vilanterol Brand 37 $14,496
Cromolyn Sodium Generic 32 $6,041
Azelastine Hcl Generic 253 $3,792
Ipratropium Bromide Generic 50 $1,754
Fluticasone Propionate Generic 200 $1,615

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$54,118

Medicare's payments for the services billed

Medicare patients

122

Average age 71

Services billed

6,219

91 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 56%
High blood pressure 48%
Osteoporosis 31%
Ischemic heart disease 25%
Depression 20%
Diabetes 19%
Cancer 17%
Chronic kidney disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$519 53 —
FASENRA
$283 — —
TEZSPIRE
$161 — —
NUCALA
$160 — —
AUVI-Q
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

790 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record